<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03737110</url>
  </required_header>
  <id_info>
    <org_study_id>KPL-914-C002</org_study_id>
    <secondary_id>2018-002719-87</secondary_id>
    <nct_id>NCT03737110</nct_id>
  </id_info>
  <brief_title>RHAPSODY Phase 3 Study to Assess the Efficacy and Safety of Rilonacept Treatment in Subjects With Recurrent Pericarditis</brief_title>
  <acronym>RHAPSODY</acronym>
  <official_title>Phase 3, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study With Open-label Extension, to Assess the Efficacy and Safety of Rilonacept Treatment in Subjects With Recurrent Pericarditis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kiniksa Pharmaceuticals, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kiniksa Pharmaceuticals, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of rilonacept treatment in
      subjects with recurrent pericarditis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, global, multi-center, double-blind, placebo-controlled, randomized
      withdrawal study with open-label extension, to assess the efficacy and safety of rilonacept
      treatment in subjects with recurrent pericarditis.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 6, 2018</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Actual">May 29, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to pericarditis recurrence</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who maintained Clinical Response</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of days with no or minimal pain</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with absent or minimal pericarditis symptoms</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Recurrent Pericarditis</condition>
  <arm_group>
    <arm_group_label>Rilonacept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rilonacept SC injections once weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo SC injections once weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rilonacept</intervention_name>
    <description>Rilonacept 320 mg (or 4.4 mg/kg in pediatric subjects ≥12 and &lt;18 years old) SC , followed by 160 mg (or 2.2 mg/kg in pediatric subjects ≥12 and &lt;18 years old) injections once weekly</description>
    <arm_group_label>Rilonacept</arm_group_label>
    <other_name>KPL-914</other_name>
    <other_name>Arcalyst® for Cryopyrin-Associated Periodic Syndromes (CAPS)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo SC injections once weekly</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Male or female aged 12 or older

          2. Has a diagnosis of recurrent pericarditis

          3. Must provide Informed Consent

          4. Presents with at least the third episode of pericarditis during screening.

          5. Has received Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and/or colchicine and/or
             corticosteroids (in any combination), if used, at stable dose levels (or at least not
             increased) for at least 3 days prior to first study drug administration

          6. Female subjects must be postmenopausal, or incapable of pregnancy or permanently
             sterile, or if of childbearing potential must agree to use highly-effective method of
             contraception.

          7. Must be up-to-date with all immunizations, in agreement with current local
             immunization guidelines for immunosuppressed subjects, before first study drug
             administration.

          8. Is able to adequately maintain a daily subject diary according to protocol.

          9. Agrees to refrain from making any new, major lifestyle changes that may affect
             pericarditis symptoms (e.g., changing exercise pattern) from the time that the
             informed consent form (ICF) is signed through the end of the double-blind randomized
             withdrawal period.

        Key Exclusion Criteria:

          1. Has a diagnosis of pericarditis that is secondary to specific prohibited etiologies.

          2. Has a history of immunosuppression, including positive human immunodeficiency virus
             (HIV) test results.

          3. Has a history of myeloproliferative disorder.

          4. Has a history of demyelinating disease or symptoms suggestive of multiple sclerosis.

          5. Has a history of active or latent Tuberculosis (TB) prior to screening

          6. Has chest x-ray at screening or within 12 weeks before receiving first administration
             of study drug, with evidence of malignancy or abnormality consistent with prior or
             active TB infection.

          7. Has a history of positive or intermediate results for hepatitis B surface antigen,
             hepatitis B core antibody, or hepatitis C virus antibody at screening.

          8. Has a history of malignancy of any organ system within the past 5 years before
             screening (other than a successfully treated non metastatic cutaneous squamous cell
             carcinoma or basal cell carcinoma and/or localized carcinoma in situ of the cervix).

          9. Has a known or suspected current active infection or a history of chronic or recurrent
             infectious disease, including, but not limited to, chronic renal infection, chronic
             chest infection, sinusitis, recurrent urinary tract infection, or an open, draining
             infected skin wound.

         10. Has had an organ transplant.

         11. In the investigator's opinion, has a history of alcoholism or drug/chemical abuse
             within 2 years before screening.

         12. Has a known hypersensitivity to rilonacept or to any of its excipients.

         13. Has received an investigational drug during the 30 days before screening or is
             planning to receive an investigational drug (other than that administered during this
             study) or use an investigational device at any time during the study.

         14. In the investigator's opinion, has any other medical condition that could adversely
             affect the subject's participation or interfere with study evaluations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Paolini, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Kiniksa Pharmaceuticals, Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Heart Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis and Rheumatology of Georgia</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loretto Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60644</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconness MC</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - PPDS</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester General Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University School of Medicine</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>05229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Consultants of Philadelphia</name>
      <address>
        <city>Yardley</city>
        <state>Pennsylvania</state>
        <zip>19067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovoyage</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orion Medical</name>
      <address>
        <city>Pasadena</city>
        <state>Texas</state>
        <zip>77505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Healthcare</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Vermont Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hosptial</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Core Research Group</name>
      <address>
        <city>Milton</city>
        <state>Queensland</state>
        <zip>4064</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HeartCare Partners Clinical Research Unit</name>
      <address>
        <city>Milton</city>
        <state>Queensland</state>
        <zip>4064</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital</name>
      <address>
        <city>Woodville</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hobart Hospital</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Health, Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GenesisCare - Cardiology Research</name>
      <address>
        <city>Doncaster East</city>
        <state>Victoria</state>
        <zip>3109</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Murdoch</city>
        <state>Western</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HaEmek Medical Center</name>
      <address>
        <city>Afula</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bnai Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Health Corporation</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edith Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah University Hospital Mount Scopus</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galilee Medical Center</name>
      <address>
        <city>Nahariya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center - PPDS</name>
      <address>
        <city>Petach Tiqwa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assaf Harofe Medical Center</name>
      <address>
        <city>Tzrifin</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZIV Medical Center</name>
      <address>
        <city>Zefat</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto G Gaslini Ospedale Pediatrico IRCCS</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Fatebenefratelli Sacco - Ospedale Fatebenefratelli e Oftalmico</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesù</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.rhapsodystudy.com</url>
    <description>RHAPSODY study information</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 30, 2018</study_first_submitted>
  <study_first_submitted_qc>November 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2018</study_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pericarditis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rilonacept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

